Trending Now
BUSINESS
U.S. Food and Drug Administration Places Clinical Hold On Cellectis MELANI-01...
Cellectis a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed...
MEDICAL DEVICES
MANUFACTURING
Servier Appoints MaSTherCell For The Development Of Its CAR-T Cell Therapy...
GERMANTOWN, MD--(Marketwired - January 20, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...
JOURNAL SPOTLIGHT
PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers
LAGUNA HILLS, Calif., Dec. 27, 2016 - PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and...
EVEN MORE NEWS
